MR-PET for Staging and Assessment of Operability in Ovarian Cancer - a Feasibility Study

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Ovarian Neoplasms
Interventions
RADIATION

MR-PET

The MR-PET will be performed with the Biograph mMR system (Siemens Healthcare, Erlangen, Germany). This system integrates a 3Tesla MRI and PET scan which makes simultaneous acquisition of whole-body MRI and PET images possible. The Biograph mMR holds the CE mark and was FDA approved in June 2011. The Biograph mMR is intended to be used in the Academical hospita! Maastricht for standard patient care. The radiotracer that will be used is 18F-Iabeled fluorodeoxyglucose (18F-FDG), according to standard PET -protocol.

Trial Locations (1)

6229 HX

Maastricht University Medical Centre, Maastricht

All Listed Sponsors
lead

Maastricht University Medical Center

OTHER

NCT02334371 - MR-PET for Staging and Assessment of Operability in Ovarian Cancer - a Feasibility Study | Biotech Hunter | Biotech Hunter